Skip to main content
. 2021 Feb 25;12:643692. doi: 10.3389/fimmu.2021.643692

Table 1.

Summary table for the hallmark breast cancer studies using single-cell technologies.

Technology Sample/data Main findings Clinical significance References
The complexity of tumor-infiltrating lymphocytes (TILs) scRNA-seq (10X Genomics) 6,311 flow-sorted CD3+CD45+ T cells from two samples of TNBC Discovery of minor subgroups of TILs that were related to immune-suppression Biomarkers of the minor distinct TILs may serve as prognostic factors or therapeutic targets (11)
scRNA-seq (10X Genomics) Paired samples of pre- (998 cells) and post-neoadjuvant chemotherapy (1,499 cells) collected from 4 BRCA patients ICOSL+ B cells boost anti-tumor immunity by enhancing the effector to regulatory T cell ratio The critical role of the B cell subset switch in chemotherapy response, which has implications in designing novel anti-cancer therapies. (12)
Decomposition of tumor immune microenvironment using scRNA-seq scRNA-seq (Fluidigm C1) 515 cells from 11 patients representing the four subtypes of breast cancer T lymphocytes and macrophages both display immunosuppressive characteristics The characteristics of different BRCA subtypes that are shaped by tumor cells and immune cells in TME (13)
scRNA-seq (inDrop); single-cell VDJ sequencing (10X Genomics) 45,000 cells captured in the normal and malignant breast tissues, lymph nodes, and peripheral blood of 8 treatment-naive patients Despite the significant similarity between normal and tumor tissue-resident immune cells, continuous phenotypic expansions specific to the TME was observed Support a model of continuous activation in T cells and do not comport with the macrophage polarization model in cancer (15)
Spatial mapping of single-cell RNA-seq data Spatial Transcriptomics (in-house) Tumor tissue sections from BRCA patients diagnosed with HER2+ subtype Demonstration of the heterogeneous nature of tumor-immune interactions and reveal interpatient differences in immune cell infiltration patterns Potential for an improved stratification and description of the tumor-immune interplay, which is likely to be essential in treatment decisions (16, 17)
Dissecting the tumor microenvironment using single-cell mass cytometry Single-Cell Mass Cytometry 26 million cells from 144 human breast tumors including and 50 non-tumor tissue samples Relationship analyses between tumor and immune cells revealed characteristics of TME related to immunosuppression and poor prognosis TME-based classification of BRCA will facilitate the identification of individuals for precision medicine approaches (20)
Imaging mass cytometry 855,668 cells in 381 images (289 tumors, 87 healthy breasts, and 5 liver controls) Multicellular features of TME and novel subgroups of breast cancer that are associated with distinct clinical outcomes Spatially resolved, single-cell analysis can characterize intratumor phenotypic heterogeneity with the potential to inform patient-specific diagnosis (23)